I wish I knew the answers! :)I think it's a bad time for pharmaceuticals in general. Both the political and economic climate are tough for drug companies right now. And a small cap like Lannett can swing wildly with relatively little action. Plus, the whole Farber/Perrigo buyout arrangement was handled extremely poorly this past summer. Farber is an octagenarian, so we shareholders need to pay attention to the inevitable changing of the guard.I am in agreement, though, that health care and pharmaceuticals are growth industries as the baby boomers age. I suspect generics will play an ever-increasing role as costs become a more important issue.So for now I hold and watch....
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. M